OAKLAND, Calif. (April 18, 2019) – California Cannabinoids, Inc. has announced that internationally renowned cannabis scientific expert Paul F. Daley, B.S., Ms.S., Ph.D. has joined the company as Chief Scientific Officer, bringing an important scientific research partner and product developer to the brand.
With more than 30 years of experience in analytical toxicology and environmental sciences, Dr. Daley will manage all science-related product development and testing for the company as it expands the production and sale of Doug’s Varin™ — a rare and highly sought-after cannabis formulation which contains the highest concentrations of THCV available in the marketplace.
Dr. Daley’s scientific career includes postdoctoral research at Université Laval in Quebéc, P.Q., Canada, and thirty years at the Lawrence Livermore National Laboratory as Environmental Scientist and Chemist. Since 2007 he has been Research Director and Senior Research Chemist at the Alexander Shulgin Research Institute. An entrepreneurial scientist, Dr. Daley also developed a cannabis distillation company, and was its laboratory general manager and quality control officer.
“We are honored to have such a distinguished and widely recognized scientific expert join our team. Paul will be critical to unleashing the reputed benefits of this amazing cannabinoid as we expand Doug’s Varin products in the marketplace,” said California Cannabinoids CEO David Lampach. “His knowledge and recognized leadership in the cannabis sector will bolster our drive for innovation and research to provide the benefits of Doug’s Varin to cannabis users who have been long awaiting its release.”
Dr. Daley has authored over sixty peer-reviewed publications in integrated pest management, plant photosynthesis, environmental chemistry, and analytical instrumentation including co-authoring The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, published by Transform Press in 2011.
“I am thrilled to be part of the team who will finally make Doug’s Varin available to cannabis users who have been requesting access for its amazing health benefits,” said Daley. “We are currently formulating an array of new products which are expected to be introduced this summer. This is an exciting time to be in the cannabis business.”
This first distribution of Doug’s Varin™ began in February 2019, at five SPARC™ locations in the San Francisco Bay Area with the introduction of two THCV-rich vape pen product lines: Doug’s Varin™ ORIGINAL (1:1 THCV/THC) and Doug’s Varin™ RELIEF (1:1 THCV/CBD). Both contain 25% to 30% THCV cannabis oil,found naturally in a full spectrum extraction from rare high THCV cannabis flowers, and are reputed to offer long-awaited personal health benefits. The high THCV levels are enough to activate the compound’s surprising effects.
LEVEL™ also offers a THCV enriched Tablingual™ powered by Doug’s Varin called STIMULATE and is available to cannabis users at: www.levelblends.com.
# # #
About Doug’s Varin and California Cannabinoids, Inc.: Formed in 2017, California Cannabinoids, Inc. is a California corporation based in Oakland, with the mission of providing the cannabis industry and consumers access to rare cannabinoids. The company is the exclusive provider of Doug’s Varin™ which contains the highest concentrations of tetrahydrocannabivarin (THCV) currently available in the marketplace. CEO David Lampach is a long-time industry entrepreneur, expert, grower and advocate for clean, safe cannabis. Prior to founding California Cannabinoids, he was Co-Founder and CEO of Steep Hill Labs and served a consultant to several states concerning the creation and implementation of various aspects of medical and recreational cannabis regulation. To learn more, visit: DougsVarin.com.
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers